Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo

What Was Tested

The paper reports a study of Endothelin-1, published as a randomized controlled trial.

Insulin and angiotensin II (Ang II) are involved in the regulation of endothelin-1 (ET-1).

This study investigates their possible influence on plasma levels of ET-1 in humans.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Twenty patients with essential hypertension were included in a randomized, double-blind, placebo-controlled crossover study of 4 weeks' treatment with losartan, a selective type 1 angiotensin (AT1) receptor antagonist.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Endothelin-1 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Endothelin-1.

The comparison arm used a placebo, so changes seen with Endothelin-1 could be set against what happens without it.

Each person switched between Endothelin-1 and the comparison at some point, usually with a gap in between.

The effect was evaluated in the fasting state and during acute hyperinsulinemia physiologically induced by oral glucose ingestion (OGTT) and by euglycemic glucose clamp.

What Was Measured

This study investigates their possible influence on plasma levels of ET-1 in humans.

The subject headings attached to it are Antihypertensive Agents, Endothelin-1, Fasting, Glucose Clamp Technique, Glucose Tolerance Test, Hyperinsulinism and Hypertension.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Endothelin-1.

The publication is from 1998 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Endothelin-1 compound page, all human trials.